STOCK TITAN
  1. Home
  2. News
  3. BMRN

BioMarin Pharmaceuticals Inc - $BMRN STOCK NEWS

Welcome to our dedicated page for BioMarin Pharmaceuticals news (Ticker: $BMRN), a resource for investors and traders seeking the latest updates and insights on BioMarin Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioMarin Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioMarin Pharmaceuticals's position in the market.

News
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV
Rhea-AI Summary

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will be presenting at the BofA Securities 2024 Healthcare Conference on May 15, 2024, in Las Vegas, NV. Alexander Hardy, President, and CEO of BioMarin, will be presenting at 10:00am PT / 1:00pm ET. The presentation will be available via live audio webcast and archived on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting
Rhea-AI Summary

BioMarin Pharmaceutical Inc. presented positive new data at the 2024 Pediatric Endocrine Society Annual Meeting, highlighting the safety and efficacy of VOXZOGO® (vosoritide) in children with achondroplasia and other growth-related conditions. Results from multiple studies showed significant improvements in annualized growth velocity and height standard deviation, particularly in children with Noonan syndrome, ACAN deficiency, and NPR2 mutations. Data also demonstrated VOXZOGO's potential to positively impact growth beyond achondroplasia. Clinical trials for growth-related conditions are ongoing, with promising results for children with achondroplasia who initiated treatment during adolescence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
none
-
News
BioMarin Reports Record Financial Results for the First Quarter 2024
Rhea-AI Summary
BioMarin Pharmaceutical Inc. reported record financial results for the first quarter of 2024, with total revenues reaching $649 million, a 9% year-over-year increase. GAAP diluted earnings per share rose by 70% year-over-year to $0.46, while non-GAAP diluted earnings per share increased by 18% to $0.71. VOXZOGO® net product revenues surged by 74% year-over-year to $153 million, with over 100% increase in children treated. Full-year 2024 guidance was reaffirmed, with non-GAAP operating margin and EPS raised. Strategic priorities focused on accelerating high-value programs, with a strong emphasis on the VOXZOGO opportunity. BioMarin's financial performance showcased growth and profitability enhancements, with an outlook towards operational excellence and value creation for stakeholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.9%
Tags
earnings
News
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
Rhea-AI Summary
BioMarin Pharmaceutical Inc. to host a conference call on April 24, 2024, to discuss first quarter financial results and business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
conferences earnings
-
News
New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
Rhea-AI Summary
BioMarin Pharmaceutical Inc. announces positive results from an investigator-sponsored Phase 2 study of VOXZOGO in children with hypochondroplasia and achondroplasia, showcasing significant growth improvements and quality of life enhancements. The company also highlights the long-term efficacy and safety of VOXZOGO in children with achondroplasia, with promising data presented at the 2024 ACMG Annual Clinical Genetics Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
none
-
News
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
Rhea-AI Summary
BioMarin Pharmaceutical Inc. appoints Cristin Hubbard as executive vice president and chief commercial officer, bringing over 20 years of experience in the biopharmaceutical and diagnostics industries. Hubbard will lead global commercial operations from May 20, succeeding Jeff Ajer. Hubbard's background includes roles at Roche Pharma and Roche Diagnostics, demonstrating expertise in lifecycle management, growth strategies, and leadership in various therapeutic areas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
management
News
BioMarin Scheduled to Participate in March Investor Conferences
Rhea-AI Summary
BioMarin Pharmaceutical Inc. (BMRN) announced participation in four investor conferences in March, with Brian Mueller, CFO, scheduled for fireside chats and 1x1 meetings. The conferences include Cowen 44th Annual Healthcare Conference, Leerink Partners Global Biopharma Conference, Jefferies Biotech on the Bay Summit, and Barclays 26th Annual Global Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
conferences
-
News
BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024
Rhea-AI Summary
BioMarin Pharmaceutical Inc. reports strong financial results for FY'23 with total revenues of $2.42 billion, a 15% YoY increase, and GAAP diluted earnings per share of $0.87 (+16% YoY). VOXZOGO® net revenues surged to $146 million in Q4'23 (+118% Q/Q) and $470 million for FY'23 (+178% YoY). The 2024 financial outlook anticipates double-digit total revenue growth and significant non-GAAP operating margin expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
earnings
-
News
BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET
Rhea-AI Summary
BioMarin Pharmaceutical Inc. (BMRN) will host a conference call and webcast on February 22, 2024, to discuss the financial results and provide a general business update for the fourth quarter and full-year 2023. Interested parties can access the live audio webcast via the investor section of the BioMarin website. The call will be archived on the site for one week following the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
conferences earnings
News
BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress
Rhea-AI Summary
BioMarin Pharmaceutical Inc. announced new data on ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) to be presented at the 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress. Results from a Phase 2 study showed that median factor VIII (FVIII) activity at year seven remained in the mild hemophilia range and mean annualized bleeding rate (ABR) for treated bleeds over the full follow-up period decreased by 96% from baseline for adults with severe hemophilia A in the 6x1013 vg/kg dose cohort. Additional studies will be shared, including preliminary results from GENEr8-INH, a Phase 1/2 study evaluating the safety and efficacy of ROCTAVIAN in participants with active and prior FVIII inhibitors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.37%
Tags
conferences
Stock BMRN logo
BioMarin Pharmaceuticals Inc

Nasdaq:BMRN

BMRN Rankings

#611 Ranked by Market Cap
#2446 Ranked by Stock Gains
N/A Ranked by Dividends

BMRN Stock Data

15.68B
187.23M
0.84%
100.76%
1.62%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NOVATO

About BMRN

biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment